BRAF分子检测在结直肠癌中的研究进展

Research of BRAF-biomarker detection in colorectal cancer

目的结直肠癌经典化疗方案是以氟尿嘧啶为主的联合化疗。近年来,抗表皮生长因子受体(EGFR)的靶向治疗被广泛讨论,且在结直肠癌的治疗中取得一定疗效。目前,对抗EGFR靶向治疗的疗效研究已经涉及到相关基因的表达状态,如既往探讨较多的K-Ras基因表达,新近又发现BRAF基因的突变在结直肠癌的发展以及抗EGFR靶向药物的疗效方面有重要意义。本文就BRAF基因在结直肠癌发生发展过程中的作用机制,以及作为临床预后监测及耐药预测指标的意义作一综述。

Objective Fluoropyrimidine-based chemotherapy regimens are considered as standard treatment in colorectal cancer.The epidermal growth factor receptor（EGFR） represents an important target for cancer treatment.Despite the roll of K-Ras mutations in the targeted therapy of colorectal cancer,BRAF mutations have emerged as an important predictive marker in the development of colorectal cancer and efficacy in EGFR targeted therapy.This article aims to review the mechanism of BRAF gene in the development of colorectal cancer,and its relevance of predicting clinical outcomes and drug resistance.